#$%^&*AU2019279945A120200116.pdf#####ABSTRACT The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.1/42 *Ve~~~10f0* Oftog~0m~gBU~l ISO 120 140 10 0 6 -60 400 20 20 0 &ay-? Woredamp day- b.oor dwap 4w C9 d omp bf trX M Afte trmem0I~ nU~e0A MWtOnnine D Ovehicle *Abl4et ilt 40 "yg10O M* 140 3S 30 10 20E Is 60 ioi 20 wo, ttooi" Figure 1: Blood glucose and plasma insulin levels before and aftertreatment.
